An open-label, phase Ib dose-expansion study to assess the efficacy of CD137/FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, recurrent programmed cell death ligand-1 (PD-L1)-positive head and neck squamous cell carcinoma (HNSCC).

Authors: Rachna T. Shroff, Dejan Radonjic, Jianrui Hou, Marta Puig, Jean-Pascal H. Machiels

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2684

Source: Full article

TPS2684